ASCO GU 2018: Statin use and Outcomes of Patients with mCRPC Being Treated with Abiraterone

San Francisco, CA ( Epidemiologic studies have demonstrated an association between statin use and improved prostate cancer specific mortality. Several different biologic mechanisms for such an effect have been proposed, including a potential role in reducing androgen precursor bioavailability. The authors have hypothesized that statins may therefore improve outcomes specifically in patients treated with the CYP17 inhibitor Abiraterone (ABI). Di Lorenzo (2017) recently published an analysis of 187 pts showing a relationship between ABI and improved survival (OS).


Disease outcome and statin use were assessed retrospectively in locally advanced or metastatic CRPC patients receiving Abi in British Columbia, Canada. The Kaplan-Meier method was used to estimate survival times, Cox proportional hazards and logistic regression were used to investigate factors potentially prognostic of overall survival and PSA response respectively. A multivariable model was constructed using factors with limited missing data and known biologic rationale. Impact of statins was then assessed adjusting for factors included in the multivariable model.


301 patients receiving Abi were assessed, of whom 84 (28%) were statin users. Median OS of Abi patients was 11.3 months for non-statin users and 16.2 months for statin users (hazard ratio = 0.79, 95% CI = 0.61-1.03, p = 0.079). Effect of statin use remained borderline after adjusting (n = 279, hazard ratio = 0.78, 95% CI = 0.59-1.04, p = 0.087) for age, prior prostatectomy, radiation, Docetaxel, time from diagnosis, neutrophils-lymphocyte ratio and presence of metastases. Forty-eight percent of statin users and 37% of non-statin users had a PSA response (multivariable odds ratio = 1.59, 95% CI = 0.91-2.78, p = .11).


Although this study entails a small sample size, the data showed a trend that statins may mildly enhance the anti-tumor effects of ABI in CRPC patients. These results support the findings of Di Lorenzo et al. (2017), and suggest that depletion of de novo cholesterol production may further limit androgen synthesis in concert with CYP17A1 inhibition. Naturally additions studies are warranted.

Presented by: Jacob A Gordon

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, Twitter:@GoldbergHanan at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA

1. Di Lorenzo G, Sonpavde G, Pond G, et al. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European urology focus 2017.